Aug 31, 2015 - Eli Lilly has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat
Aug 28, 2015 - Eli Lilly (LLY) announced that the FDA has approved its diabetes drug, Synjardy, for the treatment of patients with type II diabetes.
Aug 27, 2015 - Oncolytics Biotech (ONCY) completed enrolling patients in a phase II study on Reolysin for the treatment of non-small cell lung cancer.
Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.
Aug 26, 2015 - Eli Lilly and Company announced that it has received a favorable ruling in a lawsuit related to the infringement of vitamin regimen patent for Alimta.
Aug 25, 2015 - Exelixis, Inc. (EXEL) announced that its oncology drug, Cometriq has received Breakthrough Therapy designation from the FDA.
Aug 25, 2015 - Epizyme, Inc. (EPZM) announced that its investigational new drug application for tazemetostat for the treatment of adults and pediatric patients with INI1-negative tumors or synovial sarcoma has been accepted by the FDA.
Aug 24, 2015 - Vital Therapies, Inc. (VTL) announced negative top-line data from the phase III VTI-208 study evaluating the ELAD System in patients with alcohol-induced liver decompensation.